http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013534539-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-444 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D471-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5377 |
| filingDate | 2011-07-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-09-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-2013534539-A |
| titleOfInvention | Azaindazole compounds |
| abstract | The present application relates to formula (I): [Chemical 1] An azaindole compound represented by the formula: wherein W is CR 4 or N; and R 1 , R 2 , R 3 and R 4 are defined in the specification, or a pharmaceutically acceptable salt thereof. provide. The present application also provides methods of using the compounds in the treatment of at least one CYP17 related disease (eg, cancer) and pharmaceutical compositions containing the compounds. |
| priorityDate | 2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 614.